Pinealon

Pinealon is a tripeptide — glutamic acid, aspartic acid, arginine — from the same St Petersburg research programme that produced Epithalon and the tissue-specific bioregulators. At three amino acids it is about as small as a peptide can be while still having a sequence worth discussing.

The bioregulator hypothesis is what makes this class distinctive, and it is quite different from ordinary peptide pharmacology. The proposal is not that these peptides bind receptors on the cell surface. It is that they are small enough to enter the cell, reach the nucleus, and interact with DNA directly, influencing which genes are read — and that a peptide derived from a particular tissue is relevant specifically to that tissue.

Pinealon is positioned within that scheme as the peptide concerned with brain tissue. Published work from the tradition concerns neurons under stress, particularly oxygen deprivation, and the question of whether short peptide exposure changes how they respond.

• Peptides binding DNA: That very short peptides can bind specific DNA sequences has been demonstrated in laboratory conditions. Whether that binding changes gene expression in a living cell is the step the whole hypothesis rests on.

• Tissue specificity: The claim that a peptide derived from brain tissue acts on brain tissue and not elsewhere is unusual and testable. Most signalling molecules are defined by their receptor, not by their origin.

• Neurons under oxidative stress: Most published experiments expose neuronal cultures to stress — oxygen deprivation or reactive oxygen — and measure survival. This is the main experimental model in this literature.

• Size as the mechanism: A three-residue peptide is small enough to cross membranes that exclude larger molecules. Whether that access is the point, or simply what makes the hypothesis plausible, is unresolved.

Every cell carries the same genome, and what distinguishes a neuron from a liver cell is which genes are being read. That selection is controlled by proteins called transcription factors, which bind specific stretches of DNA and switch the genes near them on or off. It is a lock-and-key arrangement operating at the level of the sequence itself.

The bioregulator proposal is that peptides only three or four residues long can participate in that recognition — binding to particular DNA sequences and influencing which genes are read. Laboratory work has shown that short peptides can bind DNA sequence-specifically, which makes the idea chemically plausible rather than fanciful.

The gap is between binding and consequence. Showing that a peptide binds a DNA sequence in a test tube is not the same as showing it enters a living cell in useful quantity, reaches the nucleus, competes with the transcription factors already there, and changes what the cell produces. Each of those steps is required for the hypothesis to hold, and the published work establishes them with varying degrees of firmness.

The demonstrations of short-peptide DNA binding are real and published. Beyond that, the position is the same as for the rest of this tradition: a large literature, mostly Russian-language, mostly from the institute that developed these compounds, with limited independent replication and reporting standards below current expectations.

The work on Pinealon is cell-culture neuroprotection under stress, with animal studies from the same tradition, and there are no controlled human trials. It is supplied for laboratory research only. It is the nervous-tissue member of the bioregulator family, and the tool for testing an unusual and specific proposal: that a three-residue peptide can act on gene expression in the tissue it came from.

Epithalon is the best-known peptide from the same programme and rests on the same proposed mechanism, applied to telomere biology rather than to nervous tissue. The two are the standard pair for understanding this tradition.

Selank is a useful contrast — also a Russian neuropeptide, but one with a conventional pharmacological account involving neurotransmitter systems rather than gene regulation.